Interaction between vitamin D insufficiency and periodontitis, GCF vitamin D and LL-37 levels in well-controlled diabetes patients with periodontitis Authors: Gülnihal Eren, Oya Turkoglu, Şevki Cetinkalp, Harika Atmaca, Gül Atilla Published: 2026 ABSTRACT AbstractPurposeTo determine whether low serum vitamin D levels are inversely correlated with clinical parameters and positively correlated with gingival crevicular fluid (GCF) 25(OH)D3, 1,25(OH)2D3, LL-37 and tumor necrosis factor-α (TNF-α) levels in periodontitis patients with well-controlled type-2 diabetes (T2DM).Materials and MethodsTwenty-six well-controlled T2DM patients with periodontitis and Vitamin D insufficiency (Vit.D-IS group), and 15 well-controlled T2DM patients with periodontitis and Vitamin D sufficiency (Vit.D-S group) were included. Papilla bleeding index, bleeding on probing (BOP), supragingival plaque, clinical attachment level (CAL) and probing depth (PD) were evaluated. GCF total amounts of 25(OH)D, 1,25(OH)2D3, LL-37 and TNF-α were analyzed by ELISA. Serum 25(OH)D3 levels were determined using liquid chromatography tandem-mass spectrometry.ResultsWhole mouth CAL and BOP scores were higher in the Vit.D-IS group than those of Vit.D-S group (P=0.038, P=0.048, respectively). Whole mouth PD and plaque values were comparable in both groups. Differences were not detected in GCF 25(OH)D3, 1,25(OH)2D3, LL-37 and TNF-α levels between Vit.D-IS and Vit.D-S groups. Serum 25(OH)D3 levels were adversely associated with CAL and BOP scores (P=0.018, P=0.049, respectively). Also, GCF 1,25(OH)2D3 total amounts were positively related with GCF LL-37 total amounts (P=0.0001).ConclusionSerum 25(OH)D3 insufficiency was related to periodontal inflammation and destruction in periodontitis patients with well-controlled T2DM. However, GCF 25(OH)D3, 1,25(OH)2D3, TNF-α and LL-37 total amounts were not correlated with serum vitamin D levels. We have opinion that obtaining and maintenance of periodontal health should be included in the diabetic treatment protocol in Vitamin D deficient patients with periodontitis and well-controlled T2DM.Keywords: periodontitis, inflammation, gingival crevicular fluid, vitamin D, diabetes mellitus Introduction Vitamin D is generated by human skin after ultraviolet radiation or derived from nutritional sources and metabolized to 25-hydroxyvitamin D [25(OH)D3] (1, 2). Further metabolism of 25(OH)D3 occurs to yield active metabolite 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] (3). Vitamin D regulates the bone metabolism but it also has immunomodulatory effects on immune cells (4). It has been shown that insulin secretion is reduced in subjects with low serum vitamin D concentrations (5). As a proinflammatory cytokine, tumor necrosis factor (TNF)-α has a significant role in periodontal pathogenesis (6). Turkoglu et al. (7) showed that there were higher levels of gingival crevicular fluid (GCF) LL-37 in periodontitis patients. In experimental studies, the production of proinflammatory cytokines and antimicrobial peptides were regulated with vitamin D (8, 9). 1,25(OH)2D3 in serum down-regulates TNF-α expression (8). Moreover, there is an adverse relationship between serum 25(OH)D3 and TNF-α in type 2 diabetes mellitus (T2DM) patients with or without diabetic foot infection (10, 11). A potential mechanism by which vitamin D may lower the risk of periodontitis is through the upregulation of LL-37 expression (12). Also, it is shown that serum 25(OH)D deficiency is associated with decreased GCF LL-37 level in patients with periodontitis (13). Periodontitis is mainly caused by specific microorganisms (14). However, susceptibility and immune responses of the host have an important effect on the disease progression and severity (15). Vitamin D insufficiency is related to periodontitis severity (12, 16, 17, 18, 19). Patients with T2DM presents frequently vitamin D insufficiency (20, 21). Some researchers have observed that chronic periodontitis patients with T2DM had low vitamin D levels than those of systemically healthy chronic periodontitis patients (11, 22). They have reported that chronic periodontitis patients with T2DM had more severe periodontal destruction than chronic periodontitis patients without diabetes. But, glycemic status of these patients with T2DM has not been reported (11, 22). It has been well-known that there was a relationship between periodontitis and poorly-controlled T2DM (23). T2DM patients with good glycemic control also continue to be susceptible to infections (24). It has been stated that vitamin D might has significant effect in T2DM via expression of inflammatory cytokines (3, 25). Supplementation with vitamin D may offer therapeutic benefits in the treatment of periodontal disease, particularly among individuals with diabetes mellitus. Ramaprabha et al. (26) demonstrated that weekly oral supplementation of 60,000 IU vitamin D for eight weeks in patients with type 2 diabetes mellitus and generalized chronic periodontitis significantly improved periodontal clinical parameters, suggesting a beneficial immunomodulatory role of vitamin D. As far as we know, there is no research examining the effect of serum vitamin D insufficiency on periodontal condition and GCF biomarkers in periodontitis patients with well-controlled T2DM. The local level of 25(OH)D3 and 1,25(OH)2D3 might provide a significant knowledge about the impact of vitamin D in periodontal pathogenesis in well-controlled T2DM patients. The null hypothesis states that "serum vitamin D insufficiency would be inversely associated with clinical periodontal parameters and positively correlated with GCF 25(OH)D3, 1,25(OH)2D3, LL-37 and TNF-α levels in patients with well-controlled T2DM-associated periodontitis". The objective of this study is to estimate the impact of vitamin D insufficiency on periodontal status and GCF 25(OH)D3, 1,25(OH)2D3, LL-37, TNF-α levels of periodontitis patients with well-controlled T2DM. Materials and Methods Ethical statement This cross-sectional study was confirmed by the Ethical Committee of Ege University School of Medicine (13-5.1/12). At the beginning, all patients received detailed information and written consents were received. Sample size estimation Power analysis was performed to ensure an adequate sample size. Based on the difference in clinical attachment level (CAL) values between the Vit.D-IS and Vit.D-S groups (mean difference ≈ 0.25 mm, pooled SD ≈ 0.63 mm), the estimated effect size (Cohen's d) was 0.40, indicating a moderate effect. Assuming a two-tailed α of 0.05 and a desired power (1–β) of 0.80, the required minimum total sample size was calculated as 38 participants (G*Power 3.1). The achieved post hoc power for CAL outcomes in the present study was 0.80, confirming adequate sample size for detecting a clinically meaningful difference. Inclusion criteria The study was carried out during the months of December in 2015 and January, February, March in 2016 to decrease seasonal variability. Including criteria were: 1) older than 45 years; 2) well-controlled T2DM (HbA1c < 7%); 3) diagnosis of T2DM for ≥5 years; 4) presence of periodontitis (Stage II and III, Grade B); 5) CAL more than 3 mm and probing depth (PD) more than 5 mm at ≥ 3 non-adjacent teeth; 6) minimum 15 natural teeth (excluding third molars). Patients with well-controlled T2DM were treated according to recommendations of the Turkish Diabetes Society, HbA1c value of < 7.0%. None of T2DM patients reported having complications related to T2DM during the disease period. Patients with periodontitis were selected considering of the principles suggested by the Workshop in 2017 (27). Periodontal tissue destruction was commensurate with biofilm deposits in periodontitis patients. Radiographs were also evaluated to confirm clinical periodontal diagnosis. Exclusion criteria The exclusion criteria for all patients: 1) vitamin D or calcium supplements 2) any known systemic disease that could have an effect the progression of periodontal disease other than well-controlled T2DM 3) prophylactic antibiotics 4) pregnancy or lactation 5) any type of periodontal treatment during past 4 months 6) systemic or local antibiotic in the past 4 months. Also, individuals with less than 15 teeth and smokers were excluded. Study design Two hundred and eighty-four patients with T2DM were examined in Ege University School of Medicine Clinical of Endocrinology and Metabolic Diseases. Two hundred and forty-three patients with T2DM were not included due to they did not carry the inclusion criteria or declined to contribute after first screening. Accordingly, participants were categorized into two groups suggested by previous studies (13, 28): vitamin D insufficient group (serum 25(OH)D3 levels <50 nmol/L) (Vit.D-IS group, N=26) , vitamin D sufficient group (serum 25(OH)D3 levels ≥50 nmol/L) (Vit.D-S group, N=15). The study population was drawn from women with low socioeconomic status between the ages of 18 and 35 who gave birth in a special maternity hospital in Izmir, Turkey. A total number of 181 women who were not known to have any systemic disease or to have received treatment with antibiotics for the past 3 months participated in the present study. Smoking habits for each woman was recorded by means of a standard questionnaire and the study population was divided into three groups according to the individual's smoking status; non- smokers (women who have never smoked), light smokers (less than 10 cigarettes/day for less than 5 years), and heavy smokers (more than 10 cigarettes/day for more than 5 years). Former smokers who had quit smoking were excluded. Women who smoke 10 cigarettes/day for less than 5 years, and those who smoke 10 cigarettes/day for more than 5 years were also excluded in an attempt to make a clear discrimination between the smoking categories. All data were collected within 72 h of delivery. Informed consent was obtained from all the subjects before their enrolment. All data were collected within 72 h of delivery. Informed consent was obtained from all the subjects before their enrolment. Although there remains some lack of consensus among researchers regarding the precise threshold values defining deficiency and adequacy, the classification used in the present study aligns with the Institute of Medicine (IOM) recommendations (29). Clinical Examination PD and CAL scores at six points for each tooth were measured with a calibrated Williams probe (Hu-Friedy, Chicago, IL, USA). Papillary bleeding index (PBI) (30) and bleeding on probing (BOP) (31) were also evaluated. Additionally, supragingival plaque accumulations were recorded dichotomously (%). A calibrated examiner (G.E.) performed all clinical measurements a day before GCF sampling. The intra-examiner reproducibility of the researcher (G.E.) for CAL scores was calculated, the interclass correlation coefficient was found as 92%. Serum Vitamin D levels and GCF sampling A 5-ml blood sample per patient was picked up by venipuncture. Serum 25(OH)D3 levels were determined using a commercially available liquid chromatography tandem-mass spectrometry (Agilent LC-MS/MS 6400, Santa Clara, CA, United States). GCF samples were collected from anteriorly located teeth exhibiting PD ≥ 5 mm and CAL ≥ 3 mm. Buccal surfaces of interproximal sites were used for sampling, and well-known sampling technique was performed as suggested by Lamster et al. (32) by using paper strips and an electronic device (Periopaper, Proflow Inc., Amityville, NY, USA and Periotron 8000; Oraflow Inc., Plainview, NY, USA, respectively). Then strips were saved -400C freezer. GCF analysis Before the quantitation, 2 ml phosphate buffered saline was used for eluding the paper strip samples for 45 minutes. 25(OH)D3, 1,25(OH)2D3, TNF-α and LL-37 levels were analyzed by using a commercially available enzyme-linked immunosorbent assay kits (Boster Biological Technology, LTD Fremont, USA) according to the manufacturers' instructions. The minimum detectable limits of 25(OH)D3, 1,25(OH)2D3, TNF-α and LL-37 were 1.88 ng/ml, 4.69 pg/ml, 1.27 pg/ml and 0.94 ng/ml, respectively. The amounts were expressed as concentrations in ng/pg per milliliter. The data were reported as the GCF total amount. Statistical Analysis SPSS statistical software (SPSS, version 14.0, SPSS, Chicago, IL, USA) was used for all data analyses. The primary outcomes were CAL and BOP scores. The secondary outcomes were GCF 25(OH)D3, 1,25(OH)2D3, LL-37, TNF-α levels, and PBI, PD and plaque scores. The differences in gender distribution between study groups were estimated by Chi-square test. Numerical data were explored for normality by Shapiro–Wilk test. Clinical periodontal parameters, serum 25(OH)D3, and GCF 25(OH)D3, 1,25(OH)2D3, LL-37 and TNF-α levels were checked between two groups by Mann-Whitney U test. The correlations between clinical periodontal parameters and serum 25(OH)D3, GCF 25(OH)D3, 1,25(OH)2D3, LL-37, TNF-α levels were identified by the Spearman rank correlation. The significance level was determined at p<0.05. Results Demographic data, HbA1c and serum 25(OH)D3 levels are shown in Table 1. There were no differences in sex distribution and age between study groups (P=0.300, P=0.704, respectively). HbA1c level in Vit.D-IS group was similar to Vit.D-S group (P=0.456). Serum 25(OH)D3 levels were increased in the Vit.D-S group compared to Vit.D-IS group (P <0.0001). Table 1.Biochemical parameters.VariablesVit.D-IS groupVit.D-S group(N=26)(N=15)Gender (M/F)7/196/9Age (years)57.04 ± 6.4357.80 ± 7.20HbA1c (%)5.98 ± 0.636.13 ± 0.51Serum 25(OH)D3 (nmol/L)24.5 (7-48)75.4 (51-118)*Whole mouthPD (mm)2.75 (1.9-5.1)2.52 (1.5-3.4)CAL (mm)2.78 (2-5.2)2.53 (1.7-3.4)**BOP (%)83 (9-100)44 (6-90)**Plaque (%)100 (22-100)75 (20-100)Sampling sitesPD (mm)4 (4-5)4 (4-5)CAL (mm)4 (4-7)4 (4-5)PBI2 (0-4)1 (0-3)**Sites with plaque (%)100 (0-100)100 (0-100)GCF Volume (µl)0.62 ± 0.210.56 ± 0.19Vit.D IS: Vitamin D insufficient, Vit.D S: Vitamin D sufficient, TNF-α: tumor necrosis factor-α, LL-37: human cationic antimicrobial protein of 18 kDa (hCAP18). Data are given as median (min-max). Biochemical parameters. Vit.D IS: Vitamin D insufficient, Vit.D S: Vitamin D sufficient, TNF-α: tumor necrosis factor-α, LL-37: human cationic antimicrobial protein of 18 kDa (hCAP18). Data are given as median (min-max). Whole mouth CAL and BOP scores in the Vit.D-IS group were greater than those of the Vit.D-S group (P=0.038, P=0.048, respectively). No differences were observed in whole mouth PD and plaque scores between Vit.D-IS and Vit.D-S groups (P=0.099, P=0.322, respectively). In sampling sites, Vit.D-IS group had significantly higher PBI scores compared to Vit.D-S group (P=0.027). The differences in CAL, PD, plaque scores and GCF volume of sampling sites between Vit.D-IS and Vit.D-S groups were not statistically significant (Table 1). Table 2 presents the GCF 25(OH)D3, 1,25(OH)2D3, LL-37 and TNF-α levels. Small but nonsignificant differences were observed in the GCF 25<(OH)D3 and 1,25(OH)2D3 levels between Vit.D-IS and Vit.D-S groups (P=0.645, P=0.705, respectively), GCF LL-37 and TNF-α levels were comparable in both groups (P=0.735, P=0.705, respectively). Table 2.Biochemical parameters.BiochemicalVit.D-IS groupVit.D-S group Parameters (N=26)(N=15)25(OH)D3 (ng/site)251.9 (176.5-333.7)258.2 (229.6-281.2)1,25(OH)2D3 (pg/site)110.7 (92.4-124.8)110.9 (87.7-129.3)TNF-α (pg/site)38.3 (29-167.7)37.0 (32.3-132.8)LL-37 (ng/site)7.9 (1.7-13.7)7.7 (1.8-13.8)Vit.D IS: Vitamin D insufficient, Vit.D S: Vitamin D sufficient, TNF-α: tumor necrosis factor-α, LL-37: human cationic antimicrobial protein of 18 kDa (hCAP18). Data are given as median (min-max). Biochemical parameters. Vit.D IS: Vitamin D insufficient, Vit.D S: Vitamin D sufficient, TNF-α: tumor necrosis factor-α, LL-37: human cationic antimicrobial protein of 18 kDa (hCAP18). Data are given as median (min-max). Serum 25(OH)D3 levels were negatively correlated to whole mouth CAL and BOP scores, and this correlation was statistically significant (r= -0.368, P=0.018; r= -0.309, P=0.049, respectively). Correlations were not observed between serum 25(OH)D3 levels and whole mouth PD and plaque scores. GCF 1,25(OH)2D3 levels were associated with GCF LL-37 levels, but not with GCF TNF-α levels (r=0.530, P=0.0001; r=0.103, P=0.520, respectively). GCF TNF-α levels were associated with PD and PBI scores of sampling sites (r=0.321, P=0,041; r=0.374, P=0.016, respectively) but not with other clinical periodontal parameters (data not presented). Discussion The present study has confirmed that serum 25(OH)D3 insufficiency might be related to the severity of periodontitis in well-controlled T2DM patients. GCF 25(OH)D3, 1,25(OH)2D3, LL-37 and TNF-α total amounts were not associated with serum vitamin D levels in periodontitis patients with well-controlled T2DM. It seems that serum 25(OH)D3 insufficiency does not correlated with local levels of 25(OH)D3, 1,25(OH)2D3, LL-37 and TNF-α in these patients. It is known that HbA1c levels related to the diabetic complications (33). Diabetic patients present an exaggerated host response against inflammation; therefore, diabetes is related to periodontitis (34). A large study has shown that the association between periodontitis and diabetes weakens if control of diabetes improves (23). But it has been stated that T2DM patients with proper glycemic control continue to be susceptible to infections (24). The relationship between serum vitamin D levels and periodontitis in T2DM patients have been examined (11, 22). But it is not clear if well-controlled T2DM patients included or if the glycemic status of the patients was evaluated in these studies (11, 22). As far as we know, no studies have been performed in order to examine the relationship between serum vitamin D insufficiency and severity of periodontitis in those with well-controlled T2DM. Vitamin D was evaluated mostly in serum in many previous studies (16, 22, 35). GCF constituents are also the reflection of systemic as well as local conditions (36). So far, only two studies have investigated GCF vitamin D levels in periodontitis patients (37, 38). Balci Yuce et al. (37) evaluated GCF 25(OH)D3 concentrations in chronic periodontitis patients without T2DM by ELISA technique, and stated that local levels of 25(OH)D3 were related to periodontal inflammation. In another study, Liu et al. (38) evaluated GCF 25(OH)D3 level in aggressive periodontitis patients with radioimmunoassay technique, they stated that GCF 25(OH)D3 levels were positively related to serum 25(OH)D3 concentrations. Our findings showed that reduced serum 25(OH)D3 levels in periodontitis patients with well-controlled T2DM are significantly associated with severity of periodontitis. In addition, GCF 25(OH)D3 level was not related to 25(OH)D3 serum concentration. Performing different techniques and studying with groups having different characteristics might partly explain the different results. It has been demonstrated the relationships between serum 25(OH)D3 and periodontal disease severity (16, 39, 40). Dietrich et al. (16, 39) found that higher serum 25(OH)D3 levels are related to less gingival inflammation and low CAL scores in patients aged ≥ 50 years, but not with ones between 20 to 49 years old. Also, it has been revealed that there was a reverse association between serum 25(OH)D3 level and periodontal inflammation in postmenopausal females aged ≥ 50 years (40). In this current study, patients with 25(OH)D3 insufficiency had more periodontal disease severity than those of 25(OH)D3 sufficiency group. Our patients ages were ≥ 45 years, and our data are in line with these researchers (16, 39, 40). In this context, vitamin D may influence the host inflammatory response to oral microbial pathogens implicated in periodontitis; therefore, an interaction between reduced serum vitamin D concentrations and the severity of periodontitis may exist. Taken together, it may be stated that vitamin D potentially decrease the severity of the periodontitis in patients with well-controlled T2DM by reducing gingival inflammation. Previous study has demonstrated the connection between low serum 25(OH)D3 level and inflammation markers in elderly Irish adults (41). Peterson & Heffernan (42) observed an adverse relationship between serum 25(OH)D3 and TNF-α levels in healthy Caucasian women. Another study reported that serum TNF-α level was depended on serum 25(OH)D3 levels in adult subjects older than 55 years old (43). Additionally, 25(OH)D3 serum levels were adversely corelated to serum TNF-α concentrations in patients with diabetic foot infection (10). Up to now, there is no any study examining the GCF TNF-α levels in well-controlled T2DM patients with periodontitis and vitamin D insufficiency and sufficiency. Wang et al. (11) observed that serum 25(OH)D3 levels have a significant inverse relationship with serum TNF-α levels in periodontitis patients with T2DM. In this current study, similar GCF TNF-α levels might be caused by the fact that patients with periodontitis in both study groups had the well-controlled T2DM. Also, testing different samples such as serum might explain the contradictory results. Based on our data, serum vitamin D levels seem not to related to the GCF TNF-α levels in patients with well-controlled T2DM and periodontitis. It has been reported that GCF LL-37 levels were elevated in chronic periodontitis without T2DM compared to healthy controls (7). Our data has shown that GCF LL-37 and 1,25(OH2)D3 levels in both of Vit D-IS and Vit D-S groups were similar. One possible explanation could be the presence of patients with periodontitis in both study group. Serum 1,25(OH)₂D₃ levels are considered an unreliable marker of overall vitamin D status, as their short half-life further limits their applicability as a clinical indicator (28). It has been shown that oral epithelial cells are capable of converting 25(OH)D3 to active vitamin D 1,25(OH2)D3, and 1,25(OH2)D3 increases the synthesis of antimicrobial peptide LL-37 (44, 45). Along to same line, GCF LL-37 levels were positively related with GCF 1,25(OH)2D3 levels in our study. A recent review comprehensively discussed multiple molecular pathways linking glucose homeostasis and inflammation in diabetes-associated periodontitis. Vitamin D₃ supplementation has been shown to modulate inflammatory responses and improve glucose homeostasis, thereby mitigating pathogenic mechanisms through the regulation of several signaling pathways (46). Taken together, findings might support the opinion that serum vitamin D levels enhance innate immune defenses in patients with well-controlled T2DM-associated periodontitis. Pedersen (47) stated that serum 25(OH)D3 levels is higher during summer than rest of the year. In order to eliminate this confounder, patients examined during the late autumn and winter period were enrolled in this study. Moreover, the patients assigned in each group were very homogenous regarding diabetes status. But the cross-sectional study design could prevent us from defining the causative association between serum vitamin D levels and periodontitis in patients with well-controlled T2DM. Additionally, smoking status of the patients was established with their own sayings instead of evaluating serum cotinine levels, which is other limitation of the present study. Conclusion To summarize, positive relation between 1,25(OH)2D3 and LL-37 in GCF supports the role of local Vitamin D level on immune response. Moreover, serum 25(OH)D3 insufficiency was related to tissue inflammation and destruction in periodontitis patients with well-controlled T2DM. In other words, Vitamin D insufficiency might be responsible for the periodontal inflammation and destruction even if T2DM is well-controlled. Therefore, obtaining and maintenance of periodontal health should be included in the diabetic treatment protocol in Vitamin D deficient patients with both of periodontitis and well-controlled T2DM. Further longitudinal studies investigating local level of both 25(OH)D3 and 1,25(OH2)D3 would provide better understanding the protective role of vitamin D in periodontal tissue destruction. Acknowledgments Ege University Research Foundation for supporting the study (Grant number:2013-Diş-028). Footnotes Ethics Committee Approval: This cross-sectional study was confirmed by the Ethical Committee of Ege University School of Medicine (13-5.1/12). At the beginning, all patients received detailed information and written consents were received. Informed Consent: Participants provided informed consent. Peer Review: Externally peer-reviewed. Author Contributions: GE, OT, SC, GA participated in designing the study. GE, OT participated in generating the data for the study. GE, OT, SC, HA, GA participated in gathering the data for the study. OT participated in the analysis of the data. OT, GA wrote the majority of the original draft of the paper. OT, HA, GA participated in writing the paper. GE, OT, GA has had access to all of the raw data of the study. GE, OT has reviewed the pertinent raw data on which the results and conclusions of this study are based. GE, OT, SC, HA, GA have approved the final version of this paper. OT, GA guarantees that all individuals who meet the Journal’s authorship criteria are included as authors of this paper. Conflict of Interest: The authors declared that they have no conflict of interest. Financial Disclosure: This study was supported by a grant (2013-Diş-028) from Ege University Research Foundation. References